Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 3 | Cardio-Oncology

Fig. 3

From: Dexrazoxane prevents vascular toxicity in doxorubicin-treated mice

Fig. 3

SERPINA3N expression and plasma circulation in mice after DOX treatment. DOX increases mRNA of Serpina3n as well as circulating SERPINA3N levels after 6 weeks of treatment. A Serpina3n expression in cardiac tissue. B Serpina3n expression in aortic tissue. C Plasma concentration of SERPINA3N. At week 6 a cumulative dose of 24 mg/kg DOX and 240 mg/kg DEXRA was used. Data shows mean ± SEM. A-C Two-Way ANOVA and a Tukey correction. For each cohort: n = 8. *, **, p < 0.05, 0.01

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us